The meeting took place on 26th-28th of March in Boston (https://as-immunetolerance.com). There, large pharma, biotech, and academic researchers participated in conversations dedicated to overcome the complexity of auto-immune mediated disorders, expand opportunities through combination strategies and undertake a more precise and antigen-specific approach to novel drug development.
